Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -10611.95% is 67% below its 4-year average of -6363.74%, near the low end of its 4-year range (-10611.95%–-2887.70%).
30.98% below its 12-month average of -8101.75%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2025 (2025-09-30): -8289.71%.
EBITDA MARGIN
-10611.95%
EBITDA MARGIN AVG TTM
-8101.75%
EBITDA MARGIN AVG 3Y
-8101.75%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-30.98%
CURRENT VS 3Y AVG
-30.98%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Oculis Holding AG
Market Cap
$498.52M
EBITDA Margin
-10611.95%
TTM Avg
-8101.75%
3Y Avg
-8101.75%
5Y Avg
N/A
Market Cap
$500.52M
EBITDA Margin
10.90%
TTM Avg
10.39%
3Y Avg
7.60%
5Y Avg
5.15%
Market Cap
$502.81M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$503.93M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
Market Cap
$504.04M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
Market Cap
$505.87M
EBITDA Margin
-35.08%
TTM Avg
-77.94%
3Y Avg
-77.08%
5Y Avg
-62.83%
Market Cap
$483.54M
EBITDA Margin
21.12%
TTM Avg
19.78%
3Y Avg
18.26%
5Y Avg
11.49%
Market Cap
$516.76M
EBITDA Margin
-970.11%
TTM Avg
-861.99%
3Y Avg
-583.02%
5Y Avg
-735.09%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $498.52M | -10611.95% | -8101.75% | -8101.75% | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.52M | 10.90% | 10.39% | 7.60% | 5.15% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $502.81M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| 908 Devices Inc. (MASS)vs › | $505.87M | -35.08% | -77.94% | -77.08% | -62.83% |
| Evolus, Inc. (EOLS)vs › | $486.01M | -9.71% | -10.19% | -20.82% | -63.11% |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 21.12% | 19.78% | 18.26% | 11.49% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -970.11% | -861.99% | -583.02% | -735.09% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
Gross Margin
0.0%
EBITDA Margin
-10612.0%
Operating Margin
0.0%
Net Margin
-32724.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-09-30 | -8289.71% |
| 2025-06-30 | -7913.79% |
| 2022-03-31 | -2887.70% |
